FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average bu	rden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* King Rachel K.					2. Issuer Name and Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [FULC]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) C/O FULCRUM THERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 11/12/2024								W.		(give title		Other (s			
26 LANDSDOWNE STREET				4.	If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street) CAMBR (City)			02139 (Zip)	_									ine)		led by More		rting Persor	I	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date				Transaction ate lonth/Day/Y	Execution Date,		3. Transaction Disposed Of (D) (Instr. 3, 4) Code (Instr. 5)			ed (A) oi tr. 3, 4 a	4 and Securit		es Fo ially (D Following (I)		5. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	(A) or (D)	(A) or (D) Price		Transaction(s) (Instr. 3 and 4)				(111501. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year)			Code	ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				Code	v	(A)		Date Exercisab		Expiration Date	Title	Amour or Number of Shares	er						
Stock Option (right to buy)	\$3.64	11/12/2024		A		60,000		(1)	1	1/11/2034	Common Stock	60,00	00	\$0	60,000)	D		

Explanation of Responses:

1. This option was granted on November 12, 2024 and is scheduled to vest in equal monthly installments until November 12, 2027, subject to continued service.

/s/ Alan Musso as attorney-infact for Rachel King

** Signature of Reporting Person Date

11/14/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.